自閉症スペクトラム（ASD）治療の市場規模、シェア、成長分析：薬物療法別、疾患別、流通チャネル別、地域別 - 産業予測、2024-2031年

世界の自閉症スペクトラム（ASD）治療の市場規模は2022年に19億2,000万米ドルと評価され、2023年の20億7,000万米ドルから2031年には37億7,000万米ドルに達し、予測期間（2024-2031年）のCAGRで7.80%の成長が予測されています。

世界の自閉症スペクトラム障害（ASD）治療市場は、認知度の向上、早期診断能力、研究開発の進歩に後押しされ、力強い成長軌道に乗っています。コミュニケーションや社会的相互作用における課題など、ASDの中核的な症状に特化した効果的な治療に対する需要が高まっています。さらに、ASD研究に対する政府の支援に加え、個別化された革新的な治療法を生み出すための継続的な取り組みが、市場の拡大をさらに後押ししています。このような成長にもかかわらず、ASD治療薬の競合情勢は依然として激しく、製薬会社は世界規模で自閉症患者のために画期的でより効率的な治療ソリューションを導入しようと努力しています。特に、米国のASD治療市場は、今後の予測期間を通じて健全なCAGRを維持すると予測されており、この分野の見通しが楽観的であることを裏付けています。各社が患者の進化するニーズに対応するため、革新的で洗練されたアプローチを続けていることから、利害関係者は今後数年間、ダイナミックでますます多様化する市場情勢を予測することができます。

目次

イントロダクション

• 調査の目的
• 定義
• 市場範囲

調査手法

• 情報調達
• 二次データソースと一次データソース
• 市場規模予測
• 市場の想定と制限

エグゼクティブサマリー

• 市場概要見通し
• 供給需要動向分析
• セグメント別機会分析

市場力学と見通し

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• ポーターの分析

主な市場の考察

• 技術分析
• バリューチェーン分析
• 市場のエコシステム
• ケーススタディ分析
• 規制情勢
• イノベーションマトリクス
• 主な投資の分析
• 主な成功要因
• 競合の程度

自閉症スペクトラム（ASD）治療市場：薬物療法別

• 市場概要
• 抗精神病薬
• SSRI/抗うつ薬
• 興奮剤
• 睡眠薬
• その他

自閉症スペクトラム（ASD）治療市場：疾患別

• 市場概要
• 自閉症
• アスペルガー症候群
• 広汎性発達障害（PDD）
• その他

自閉症スペクトラム（ASD）治療市場：流通チャネル別

• 市場概要
• 病院薬局
• ドラッグストア・薬局
• オンライン薬局

自閉症スペクトラム（ASD）治療市場規模：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ（MEA）
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場における最近の活動
• 主要企業の市場シェア（2023年）

主要企業プロファイル

• Curemark, LLC（US）
• Alembic Pharmaceuticals Limited（India）
• Yamo Pharmaceuticals（US）
• PaxMedica（US）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Aurobindo Pharma Ltd.（India）
• Otsuka Holdings Co. Ltd.（Japan）
• Janssen Pharmaceuticals, Inc.（US）
• Teva Pharmaceutical Industries Ltd.（Israel）
• H. Lundbeck A/S（Denmark）
• AbbVie Inc.（US）
• Eli Lilly and Company（US）
• Pfizer Inc.（US）
• Novartis International AG（Switzerland）
• Neurocrine Biosciences, Inc.（US）
• Acadia Pharmaceuticals Inc.（US）
• Intra-Cellular Therapies, Inc.（US）
• Amedisys, Inc.（US）
• Sage Therapeutics, Inc.（US）
• Purdue Pharma L.P.（US）
• Horizon Therapeutics plc（Ireland）
• Karuna Therapeutics, Inc.（US）

Global Autism Spectrum Disorder Therapeutics Market size was valued at USD 1.92 billion in 2022 and is poised to grow from USD 2.07 billion in 2023 to USD 3.77 billion by 2031, growing at a CAGR of 7.80% during the forecast period (2024-2031).

The global autism spectrum disorder (ASD) therapeutics market is on a robust growth trajectory, fueled by heightened awareness, early diagnosis capabilities, and advancements in research and development. The demand for effective treatments that specifically address the core symptoms of ASD, including challenges in communication and social interactions, is on the rise. Additionally, ongoing initiatives to create personalized and innovative therapies, complemented by government support for ASD research, are further propelling market expansion. Despite this growth, the ASD therapeutics landscape remains intensely competitive, with pharmaceutical companies striving to introduce groundbreaking and more efficient therapeutic solutions for individuals with autism on a global scale. Notably, the US ASD therapeutics market is projected to sustain a healthy compound annual growth rate (CAGR) throughout the upcoming forecast period, underscoring the optimistic outlook for the sector. As companies continue to innovate and refine their approaches in response to the evolving needs of patients, stakeholders can anticipate a dynamic and increasingly diversified market landscape in the years to come.

Top-down and bottom-up approaches were used to estimate and validate the size of the global autism spectrum disorder therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

global autism spectrum disorder therapeutics Market Segmental Analysis

Global Autism Spectrum Disorder Therapeutics Market is segmented by Drug Therapy, Disease, Distribution Channel, and region. Based on Drug Therapy, the market is segmented into Antipsychotic Drugs, SSRIs/Antidepressants, Stimulants, Sleep Medications, and Others. Based on Disease, the market is segmented into Autistic Disorder, Asperger Syndrome, Pervasive Developmental Disorder (PDD), and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the global autism spectrum disorder therapeutics Market

The escalating prevalence of autism spectrum disorder (ASD) worldwide is a critical driver propelling the growth of the global ASD therapeutics market. Current statistics from the World Health Organization reveal that approximately 1 in 160 children is diagnosed with ASD, fostering an urgent need for effective therapeutic interventions. This rise in diagnosis has consequently increased awareness and facilitated earlier detection of ASD, compelling healthcare providers and policymakers to prioritize the development of targeted therapies. The sustained drive towards innovative research and development is anticipated to yield a wave of novel treatments, thereby addressing the significant unmet needs within the ASD patient population and expanding market opportunities.

Restraints in the global autism spectrum disorder therapeutics Market

The global autism spectrum disorder (ASD) therapeutics market faces significant restraints primarily due to the intrinsic complexity of ASD. This heterogeneous condition exhibits a broad spectrum of symptoms and varying responses to treatments among individuals, complicating the establishment of standardized therapeutic approaches. Furthermore, the unclear etiology and underlying mechanisms of ASD impede efficient drug development, leading to challenges in creating targeted interventions. This variability results in slower drug approval processes, along with potential limitations in the effectiveness of available therapies. Consequently, the multifaceted nature of ASD underscores the difficulties in advancing therapeutics in this market.

Market Trends of the global autism spectrum disorder therapeutics Market

The global autism spectrum disorder (ASD) therapeutics market is witnessing significant trends that reflect innovations and shifting approaches in treatment modalities. There is a heightened focus on early intervention strategies and personalized therapies informed by genetic insights, aiming to provide tailored solutions for individuals with ASD. Furthermore, robust investments in research and development are paving the way for novel treatment options. The integration of technology, particularly in behavioral interventions and remote monitoring, is enhancing accessibility to care, thereby broadening the outreach to affected families. Increased awareness and advocacy are further accelerating the demand for effective treatments, prompting pharmaceutical companies to intensify their efforts in this crucial therapeutic landscape.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case study Analysis
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Autism Spectrum Disorder Therapeutics Market by Drug Therapy

• Market Overview
• Antipsychotic Drugs
• SSRIs/Antidepressants
• Stimulants
• Sleep Medications
• Others

Autism Spectrum Disorder Therapeutics Market by Disease

• Market Overview
• Autistic Disorder
• Asperger Syndrome
• Pervasive Developmental Disorder (PDD)
• Others

Autism Spectrum Disorder Therapeutics Market by Age Group

• Market Overview
• Hospitals Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

Autism Spectrum Disorder Therapeutics Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Curemark, LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alembic Pharmaceuticals Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Yamo Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PaxMedica (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co. Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H. Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurocrine Biosciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acadia Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intra-Cellular Therapies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amedisys, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sage Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Purdue Pharma L.P. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Therapeutics plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karuna Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments